PRESS RELEASE

Notice of Interim Results

Guildford, UK - 23 August 2021: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ending 30 June 2021 on 28 September 2021.

Miroslav Reljanović, Executive Chairman, and Richard Barfield, Chief Financial Officer, will host a virtual presentation and conference call for analysts at 10.30am BST on the day of the results.

ENDS

Enquiries:

Ergomed plc                                                                              Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)          

Richard Barfield (Chief Financial Officer)           

Numis Securities Limited                                                         Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)          

James Black (Broker)   

Peel Hunt LLP                                                                             Tel: +44 (0) 20 7418 8900

James Steel / Dr. Christopher Golden

Consilium Strategic Communications                                      Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal                                                     ergomed@consilium-comms.com

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com.